You are here

Mavyret

Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales

Motley Fool

Fri, 11/22/19 - 10:04 am

Enanta Pharmaceuticals

FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?

Endpoints

Mon, 09/30/19 - 10:42 am

FDA issues safety warning for newer hepatitis C drugs following patient deaths

Biopharma Dive

Wed, 08/28/19 - 11:02 pm

Gilead Sciences

AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries

Fierce Pharma

Tue, 11/13/18 - 10:24 pm

Medicines Patent Pool

Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019

Bloomberg

Tue, 08/7/18 - 11:24 am

Express Scripts

Gilead Sciences

AbbVie surprised investors with its hepatitis C success. Will it last?

Biopharma Dive

Sat, 08/4/18 - 11:43 am

2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited

Motley Fool

Fri, 07/27/18 - 07:13 pm

As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam

Fierce Pharma

Fri, 07/27/18 - 07:05 pm

This Small Biotech Is Building on a Surprising Success

Motley Fool

Wed, 04/25/18 - 09:32 am

Enanta Pharmaceuticals

5 Must-See Quotes From AbbVie's Management

Yahoo/Motley Fool

Fri, 03/16/18 - 09:27 am

Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short

Fierce Pharma

Thu, 02/8/18 - 09:14 am

Gilead Sciences

5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them

Motley Fool

Sun, 01/21/18 - 10:53 am

Bristol-Myers Squibb

There's a Lot to Like in AbbVie's Q3 Update

Motley Fool

Fri, 10/27/17 - 02:44 pm

AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games

Marketwatch

Sun, 08/6/17 - 09:48 pm

Gilead Sciences

Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?

Motley Fool

Sat, 08/5/17 - 09:44 am

Gilead Sciences

AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition

Fierce Pharma

Fri, 08/4/17 - 11:32 am